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Identity 




Structure of PAX8 gene. 
Description 
62924 bp, 11 exons, cDNA 4065 bp. 
Transcription 
Five different isoforms due to alternative splicing. 
Protein 
Description 
Pax8 is a transcription factor. The molecular weight of 
the unprocessed precursor is ~48 kD. Five different 
isoforms have been described (a-e): 
-Isoform a (450 aa, 4065 bp) 
-Isoform b (387 aa, 3876 bp, lack exon 8; mass of ~42
kD) 
-Isoform c (398 aa, 3986 bp, lack exons 7, 8; mass of 
~43 kD) 
-Isoform d (321 aa, 3755 bp, lack exon 8; mass of ~35
kD) 
-Isoform e (287 aa, 3653 bp, lack exons 8, 9, 10; mass 
of ~31 kD) 
Expression 
Pax8 is expressed in embryonal human tissues, in 
particular in the developing thyroid gland, kidney,  
Müllerian structures, and nervous system (e.g. otic 
placode), and in the human placenta. During thyroid 
development PAX8 is expressed in the thyroid anlage. 
During kidney development it is expressed in the S-
shaped body and in the early proximal tube, but is 
absent in the uretic bud and condensing mesenchyme. 
In the adult Pax8 is expressed in the thyroid gland  
kidney but it is absent in most other developed organs. 
Pax8 expression has been described in several tumor 





The paired box (PAX) genes code for a family of 
transcription factors containing a paired box domain, n 
octapeptide, and a paired-type homeo-domain. PAX 
proteins are essential for the forma-tion of several 
tissues from all germ layers in the mammalian embryo. 
Pax8 is a member of this family with a crucial role in 
the morphogenesis of the thyroid gland. It also has an 
important organogenetic role for the kidney, Müllerian 
system and inner ear. 
In the thyroid, Pax8 is a master gene that regulates 
maintenance of the differentiated thyroid follicular cell 
phenotype. As such it controls and activates the 
transcription and thyroid specific expression of the 
main proteins responsible for the functional activity of 
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(thyroperoxidase) and NIS (sodium/iodide symporter). 
In the developing Kidney PAX8 is important for renal 
vescicle formation and regulates the expression of the 
WT1 gene. 
Homology 
PAX family members (especially PAX2). 
Mutations 
Note 
Germ line PAX8 mutations are a cause of congenital 
hypothyroidism non-goitrous type 2 (CHNG2). PAX8 
rearrangement and fusion with PPARgamma1 are 
associated with the development of thyroid tumors of 
follicular cell derivation. 
Germinal 
-R31H (Sporadic, Hypoplasia, Hypothyroid) 
-Q40P (Sporadic, Hypoplasia, Hypothyroid) 
-C57Y (Familial, Hypoplasia, Hypothyroid) 
-L62R (Familial, Hypoplasia, Cystic rudiment, 
Hypothyroid) 
-R108TER (Sporadic, Ectopia with hypoplasia, 













PAX8/PPARgamma1 is an oncoprotein resulting from 
fusion of the DNA-binding domains of PAX8 to 
domains A to F of the peroxisome proliferator-
activated receptor gamma-1 (PPARgamma1). It 
involves a chromosome 3p25 and 2q13 transloca-tion, 
creating a fusion gene. This encompasses the promoter 
and the proximal coding portion of PAX8 gene and 
most of the coding sequence of the PPARgamma1 
gene. PPARgamma1 maps to 3p25, which is a 
breakpoint hot spot region for thyroid tumors of 
follicular cell origin (follicular carcino-mas and 
adenomas). 
Cytogenetics 
t(2;3)(q13;p25). Fine mapping and molecular  
characterization of the 2q13 and 3p25 translocation 
breakpoint regions revealed fusion between exons 1 to 






Translocations or inversions can give rise to the 
activation of an oncogene through its positioning near a 
strong promoter or its fusion with another gene, 
endowing the fused transcript with tumori-genic 
properties. 
PAX8 is a transcription factor with a key role in the 
maintenance of a differentiated phenotype in thyroid 
follicular cells. PPARgamma is a ligand dependent 
nuclear transcription factor highly expressed in adipose 
tissue. 
The PAX8 promoter, which is active in thyroid 
follicular cells, drives the expression of PAX8/ 
PPARgamma1 fusion protein (PPFP). Since no point 
mutations in the PPARgamma1 gene have been found 
in thyroid carcinomas and cell lines, it is speculated 
that PPARgamma1 activation resulting from the 
rearrangement plays a direct oncogenetic role. Reduced 
expression of normal PAX8 protein may also 
contribute to tumor development.  
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PD: Paired Homeobox (DNA Binding Domain); HD: Partial Homeobox; AD: Activation Domain; DBD: DNA Binding Domain; LB: Ligand 
Binding 
 
In fact, PPFP oncogenic effects could relate to 
constitutive overexpression of the full length 
PPARgamma1 domain, interference with wild-type 
PPARgamma1 or PAX8 function, novel intrinsic 
properties of PPFP, or a combination of the above. 
PPARgamma1 is thought to be the principal target of a
class of antidiabetic agents (thiazolidinediones) and 
PPFP inhibits thiazolidine-dione-induced gene 
transactivation by wild-type PPARgamma1. 
PAX8/PPARgamma1 has been identified in thyroid 
tumors of follicular cell deriva-tion characterized by a 
well developed follicular pattern of growth. These 
tumors are usually follicular carcinomas but may also 
be follicular variant papillary carcinomas or follicular 
adenomas. It has therefore been suggested that PAX8/ 
PPARgamma1 represents an early event in follicular 
cell tumorigenesis. Diagnosis of thyroid malignancies 
with a follicular growth pattern is primarily based on 
the identification of capsular or vascular invasion, 
which can only be assessed by histopathological 
examination of the surgically removed specimen. As a 
consequence, many individuals diagnosed with a 
follicular-patterned thyroid neoplasm undergo surgery. 
Since PAX8/ PPARgamma1 is associated with a 
diagnosis of carcinoma, identification of the 
rearrangement may prove a useful tool for molecular 
diagnosis. 
Thyroid follicular carcinoma 
Note 
PAX8/PPARgamma1 has been identified in thyroid 
tumors of follicular cell derivation characterized by a 
well developed follicular pattern of growth. These 
tumors are usually follicular carcinomas but may also 
be follicular variant papillary carcinomas or follicular 
adenomas. 
Disease 
Thyroid follicular carcinoma is a malignant epithelial 
tumor showing evidence of follicular cell 
differentiation and lacking the diagnostic nuclear 
features of papillary carcinoma. 
Prognosis 
PAX8/PPARgamma1 is detected in ~30-40% of 
thyroid follicular carcinomas. Follicular carcinomas 
with PAX8/PPARgamma1 are angioinvasive and may 
be aggressive. 
 
Papillary thyroid carcinoma, follicular 
variant 
Note 
PAX8/PPARgamma1 has been identified in some 
papillary thyroid carcinomas, follicular variant (up to 
30% in some series). 
Disease 
A malignant epithelial tumor showing evidence of 
follicular cell differentiation and characterized by 
distinctive nuclear features (enlargement, oval shape, 
elongation and overlapping). Follicular variant 
papillary carcinoma is composed of folli-cular 
structures without well developed papillae. 
Thyroid follicular adenoma 
Note 
PAX8/PPARgamma1 has been identified in ~5-10% of 
thyroid follicular adenoma. 
Disease 
A benign, encapsulated tumor of the thyroid showing 
evidence of follicular cell differentiation. 
Prognosis 
Thyroid follicular adenomas are benign tumors. 
Wilms' tumor 
Note 
PAX8 is expressed in Wilms' tumor and it is potentially 
involved in its induction. Pax-8 gene product resid 
upstream of wt1 in a common regulatory pathway. Two 
PAX8 isoforms, genera-ted by alternative splicing at 
the C-terminus, were found to be capable of activating 
wt1 expression. PAX8 function during mesenchymal-
epithelial cell transition in renal development is to 
induce wt1 gene expression. 
Disease 
Wilms' tumor, or nephroblastoma, is a malignant 
embryonal neoplasm of the kidney derived from 
nephrogenic blastemal cells that replicate the histology 
of the developing kidney. The tumor often shows 
divergent differentiation patterns. It is characteriz d by 
abortive tubules and glomeruli, surrounded by a 
spindled cell stroma. The stroma may include striated 
muscle, cartilage, bone, fat tissue. The genes 
predisposing to Wilms' tumor are WT1 and WT2. 
Prognosis 
Wilms' tumor is aggressive but potentially curable. 
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Ovarian carcinoma 
Note 
Aberrant transcriptional expression of PAX8 has been 
reported in epithelial ovarian cancer. 
Disease 
Malignant tumors of the ovary derived from the ovarian 
surface epithelium or its derivatives. 
Acute myeloid leukaemia 
Note 
PAX8 (with PAX2) may be a candidate for the 
upregulation of WT1 in a proportion of Acute myeloid 
leukaemias. 
Disease 
Acute myeloid leukemia is a neoplasm of myeloid 
blasts in bone marrow, blood or other tissue. 
Congenital hypothyroidism non-
goitrous type 2 (CHNG2) 
Note 
Several PAX8 mutations have been identified  
located in the conserved paired domain of PAX8. 
Disease 
Congenital hypothyroidism non-goitrous type 2 
(CHNG2) is a congenital form of hypothyroidism due 
to thyroid dysgenesis (athyreotic hypothyro-idism), 
while congenital hypothyroidism non-goitrous type 1 
(CHNG1) is due to resistance to thyroid-stimulating 
hormone (TSH). 
Primary congenital hypothyroidism is usually sporadic  
but if caused by organification defects is often 
recessively inherited. 
The mutant proteins have markedly reduced DNA 
binding with subsequent loss of transcriptional 
activation function. The mutations are thought to 
disrupt the pronounced gain of alpha helical PAX8 
content that follows the interaction of PAX8 with 
DNA: they impair the unstructured to structured 
transition that occurs during DNA recognition (loss of 
"induced fit"). As a result of the mutations PAX8 
protein cannot perform its role in activating 
transcription of its target-genes, such as TG, TPO and 
NIS. 
Marked phenotypic variability has been found within 
affected families, suggesting variable penetrance and 
expressivity of PAX8 gene defects. 
Some PAX8 mutations cause congenital hypothyro-
idism, while others mildly reduce thyroid hormone 
levels or have no detectable effect. Accordingly, 
thyroid glands of patients with PAX8 mutations are 
often small and hypoplastic, sometimes completely 
absent (athyreosis), suppor-ting the concept that PAX8 
mutations disrupt the normal growth and survival of 
thyroid cells during embryonic development. The 
reduced thyroid parenchymal mass may be unable to 
produce the required amounts of thyroid hormone. 
However, normal thyroid glands have also been 
reported in patients carrying PAX8 mutations. A small 
deletion (c.989_992delACCC) in exon 7 causing a 
frame-shift with premature stop codon after codon 277
has been described in a patient with congenital 
hypothyroidism and thyroid hypoplasia. 
Breakpoints 
 
PAX8/PPARgamma1 breakpoints and chimeric mRNA. 
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